Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment strategies for the clinical management of hematological disorders and blood cancers. - Gain insight into tests currently being used for hematological disorders and cancer diagnosis and prognosis, new developments, spending trends and revenue prospects for these technologies.
Highlights - The global market for hematology drugs and diagnostics is expected to grow from nearly $86.5 billion in 2015 to $124.3 billion in 2020 at a compound annual growth rate of 7.5% from 2015-2020. - The hematological cancers segment for this market is expected to grow from nearly $24.0 billion in 2015 to $38.2 billion in 2020 at a CAGR of 9.7% for the period 2015-2020. - The hematological disorders segment of this market over the next five years will grow from nearly $57.3 billion in 2015 to $80.0 billion in 2020 at a CAGR of 6.9% for the period 2015-2020.
Introduction & Scope
STUDY GOALS AND OBJECTIVES This report, Hematological Disorders: Drug Technologies, Diagnostics and Global Markets (PHM116B), provides an overview of the current and potential global market for hematological disorders, treatments and testing technologies. The key objective is to present a comprehensive analysis of the current state of hematological disorders and blood cancers, therapy and technology, and utilization of the various therapeutic and diagnostic modalities to prevent and treat these disorders. The report?s focus is on hematological disorder treatment strategies such as hematological therapeutics and drugs, chemotherapy, radiotherapy and immunotherapy, and other treatment modalities and testing and screening methods. The report also includes an overview of hematological disorders and staging, diagnostic tests and technologies. Important trends in the field of hematological disorders and cancer research, new developments, and sales forecasts by treatment and screening categories from 2015 through 2020 are provided in this report. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the hematological disorders and blood cancer market.
REASONS FOR DOING THIS STUDY This study was conducted to provide detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. There is an increasing need for new and innovative technologies. This industry is experiencing tremendous growth. Many diseases discussed in this report are global issues, and a need exists for newer diagnostic and treatment strategies. Some of these conditions affect children and the elderly. This study looks at most types of diagnostic and treatment strategies for the clinical management of hematological disorders and blood cancers. This BCC market research report will increase the awareness of current and emerging drugs and technologies for hematological disorders and blood cancers, including hematological disorder therapeutics, chemotherapy, radiation therapy, surgical therapy, immunotherapy and nutrition therapy.
INTENDED AUDIENCE This report is an exhaustive study on the global hematological disorders and blood cancer market, with important statistics and analysis on existing drugs and diagnostic technologies, latest trends, market structure, market size, key drug segments and trends in technology. This study contributes to the areas of market growth in hematological disorders and blood cancer prevention and treatment strategies from the point of view of manufacturers, product suppliers, healthcare providers and consumers of hematological disorder and cancer products and services. This study will be of interest largely to the pharmaceutical and biotechnology industries, as well as clinics, hospitals and research institutes. This report may also prove crucial for investment firms in the concerned sector. This report shows tests currently being used for hematological disorders and cancer diagnosis and prognosis, new developments, spending trends and revenue prospects for these technologies. The report provides market data for 2012 to 2020 and also covers commercial prospects for hematological disorders and cancer diagnostic assays, current tests in use and their future.
SCOPE OF THE STUDY The scope of this study covers instruments, reagents, testing, screening technology and the therapeutics markets for hematological disorders, including hemophilia and blood cancers. The report also discusses the regulatory environment, current technologies, new technologies, hematological disorders and cancer incidence, market projections and market share, along with latest trends, and clinical and new developments.
METHODOLOGY Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, industry news and developments, and paid and free databases. The base year of the report is 2015, with forecast data provided through 2020. Historical, base year and forecast data are provided for each market segment of this report. The report provides a comprehensive review of hematological disorders, incidence and development of these disorders, drugs currently being used and diagnostic technologies. The report also reviews technological developments, product innovations/introductions and recent strategic industry activity of major players across various product categories. Growth rates, global incidence and projections are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D and current product growth. Forecasts and projections are based on estimates such as the current trends, potential users, mergers and acquisitions, and market trends.
A comprehensive and exhaustive search of the literature on hematological disorders and blood cancers, assay development and already-marketed products, global incidence and latest drug developments was conducted. These secondary sources included scientific journals and articles, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis were also conducted. Some informal interviews were also conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources included academics, technology and consulting companies.
INFORMATION SOURCES Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of products, such as the pharmaceutical and biotechnical industries and research institutes. Data were gathered from various industry sources. BCC Research spoke with officials within the industry and consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.
Our reports have been used by over 10K customers, including:
T-Cell Lymphomas Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “T-Cell Lymphomas Global Clinical Trials Review, H2, 2018" provides an overview of T-Cell Lymphomas clinical trials scenario.This report provides top line data relating to the clinical trials on T-Cell...
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 184.108.40.206) - Pipeline Review, H2 2018 Summary Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 220.127.116.11) pipeline Target constitutes close to 23 molecules. Out of which approximately 20 molecules are developed by companies and remaining...
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 18.104.22.168) - Pipeline Review, H2 2018 Summary Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 22.214.171.124) pipeline Target constitutes close to 26 molecules. The latest report Tyrosine Protein Kinase...
20s Proteasome - Pipeline Review, H2 2018 Summary 20s Proteasome pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report 20s Proteasome - Pipeline Review, H2 2018, outlays comprehensive...
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 126.96.36.199) - Pipeline Review, H2 2018 Summary Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 188.8.131.52)...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.